A Phase 1 Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers
Enrolling
The purpose of this study is to evaluate the safety and tolerability of single ascending
doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of
ALN-4324.
Trial at a Glance
- Trial ID
- ALN-4324-001
- Condition
- Obese or Overweight Healthy Volunteers
- Drug/Treatment
- Placebo, ALN-4324
- Does this trial use a placebo?
- Yes
- Trial Type
- Interventional
- Number of Participants
- 84 participants
- Trial dates
- March 3, 2025 - June 30, 2026
For more information:NCT06845202
Who can participate?
AGE
18 to 65 Years
SEX
All
ACCEPTS HEALTHY VOLUNTEERS?
Yes
Inquire about a clinical trial
Contact Alnylam directly with any questions about our clinical trials.
Inquire about a clinical trial
Contact Alnylam directly with any questions
about our clinical trials.
about our clinical trials.
